Skip to main content

IP Update: Sep 24, 2009

Premium

Title: Methods for Determining Specificity of RNA Silencing and for Genetic Analysis of the Silenced Gene or Protein

Number: 7,592,504

Filed: June 14, 2006

Lead Inventor: Daniel Klessig, Boyce Thompson Institute for Plant Research

The invention, the patent's abstract states, comprises "methods and kits for determining the specificity of siRNAs for their targets. … Also provided is a method for performing genetic analysis of the target protein or gene using different versions of a synthetic gene to complement the phenotype induced by RNAi-mediated silencing of the target protein and/or gene of interest. Finally, a method for treating genetic disorders associated with production of mutated proteins is also disclosed."


Title: siRNA Targeting Myeloid Leukemia Sequence 1

Number: 7,592,444

Filed: Feb. 11, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing of myeloid cell leukemia sequence 1 is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs directed to myeloid cell leukemia sequence 1 by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes."


Title: siRNA Targeting Interleukin-1 Receptor-Associated Kinase 4

Number: 7,592,443

Filed: Oct. 30, 2007

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for IRAK4."


Title: siRNA Targeting Ribonucleotide Reductase M2 Polypeptide

Number: 7,592,442

Filed: June 13, 2007

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," according to the patent's abstract. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to RRM 2."


Title: Liver Cancer-Related Nucleic Acids

Number: 7,592,441

Filed: May 4, 2006

Lead Inventor: Isaac Bentwich, Rosetta Genomics

The patent, its abstract states, claims "novel polynucleotides associated with liver cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that can be used for diagnosis, prognosis, and treatment of liver cancer … [as] are methods that can be used to identify modulators of the disease-associated polynucleotides."

The patent further claims "methods and compositions for linear amplification and labeling of a targeted nucleic acid," the abstract notes. "The amplified targeted molecules may be used in hybridization techniques like Luminex and microarray analysis."


Title: Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure

Number: 7,592,325

Filed: Feb. 22, 2006

Lead Inventor: Ana Jimenez, Sylentis

The invention "relates to methods and compositions that decrease intraocular pressure of the eye," the patent's abstract states. "The compositions of the invention comprise short interfering nucleic acid molecules including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siRNAs of the invention."


Title: RNAi-Mediated Inhibition of Ocular Targets

Number: 7,592,324

Filed: Feb. 1, 2006

Lead Inventor: Allan Shepard, Alcon

The patent, its abstract states, claims the use of RNA interference for the inhibition of "ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

"Ocular hypertension is treated by administering interfering RNAs" of the invention, it adds.


Title: RNAi Modulation of RSV, PIV, and Other Respiratory Viruses and Uses Thereof

Number: 7,592,322

Filed: June 14, 2005

Inventor: Sailen Barik, Alnylam Pharmaceuticals

The invention, the patent's abstract states, "is based on the in vivo demonstration that RSV and PIV can be inhibited through intranasal administration of RNAi agents, as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the … invention provides general and specific compositions and methods that are useful in reducing RSV or PIV mRNA levels, RSV or PIV protein levels, and viral titers in a subject, e.g., a mammal, such as a human."


Title: miR-143-Regulated Genes and Pathways as Targets for Therapeutic Intervention

Number: 20090232893

Filed: May 22, 2008

Lead Inventor: Andreas Bader, Asuragen

The invention, the patent application's abstract states, "concerns methods and compositions for identifying genes or genetic pathways modulated by miR-143, using miR-143 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient, and/or treating the patient with an appropriate miRNA."


Title: Polymers and Complexes for Delivery of Nucleic Acids to Intracellular Targets

Number: 20090233359

Filed: March 17, 2009

Inventor: Young Jik Kwon, University of California, Irvine

The invention, the patent application's abstract states, comprises a complex made up of "a nucleic acid and a cationic polymer with at least one side chain coupled to the nucleic acid … [and] including an acid degradable amine-bearing ketal or acetal linkage."


Title: RNA Interference-Mediated Inhibition of Protein Tyrosine Phosphatase-1B Gene Expression Using Short Interfering RNA

Number: 20090233983

Filed: Oct. 3, 2008

Inventor: James McSwiggen, Sirna Therapeutics (Merck)

The invention, the patent application's abstract states, "concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target-validation, and genomic-discovery applications associated with insulin response. Specifically, the invention relates to small interfering RNA molecules capable of mediating RNA interference against PTP-1B polypeptide and polynucleotide targets."


Title: Signal-Activated RNA Interference

Number: 20090234109

Filed: Dec. 10, 2008

Lead Inventor: Si-Ping Han, California Institute of Technology

"The invention provides compositions and methods for signal-activated RNA interference, preferably in vivo," the patent application's abstract states. "The invention provides polynucleotides that switch between an inactive form and an active form upon covalent or non-covalent interaction with one or more specific chemical signals, such as disease-specific mRNA, miRNA, or other cellular RNA products with sequences that characterize diseased states of the cell. The interaction between the subject polynucleotides and the signals is preferably mediated by hybridization, which exposes, facilitates the formation, and/or allows the formation of a substrate that can be processed by proteins of the RNAi pathway, such as Dicer.

"The input and output of multiple different polynucleotides of the invention can form an in vivo signaling network," the abstract adds. "In addition, the multiple input signals can be integrated to modulate the activity of the subject polynucleotides."


Title: Composition Comprising siRNA-Polycation Complex for Iontophoresis

Number: 20090234271

Filed: Feb. 25, 2009

Lead Inventor: Kazuaki Kajimoto, Hokkaido University

The invention, the patent application's abstract states, comprises "a composition … capable of efficiently delivering an siRNA intradermally and of effectively suppressing the expression of a target gene by an RNAi. Provided is a composition for iontophoresis including an siRNA-polycation complex which is charged negatively."

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.